Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell
• Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
ImmunoGen Enters Multi-Target License & Option Agreement With Vertex; To Receive $15M Upfront & Up To $337M Milestone Payments
As part of the agreement, Vertex will pay ImmunoGen an upfront payment of $15 million. ImmunoGen is eligible to receive up to $337 million in option exercise fees and development and commercial milestone
Analyst Ratings for Immunogen
Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
JP Morgan Maintains Neutral on Immunogen, Raises Price Target to $9
JP Morgan analyst Daniel Wolle maintains Immunogen (NASDAQ:IMGN) with a Neutral and raises the price target from $8 to $9.
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session.
6 Analysts Have This to Say About Immunogen
Over the past 3 months, 6 analysts have published their opinion on Immunogen (NASDAQ:IMGN) stock. These analysts are…
What 6 Analyst Ratings Have To Say About Immunogen
Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.
ImmunoGen Announces Susan Altschuller On Family and Medical Leave Act; Renee Lentini Appointed Interim CFO
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, PhD, Senior Vice President and Chief Financial
ImmunoGen’s Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a preferred regimen.